Analysts Offer Insights on Healthcare Companies: Oncternal Therapeutics (ONCT), Adagene (ADAG) and Omega Therapeutics (OMGA)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncternal Therapeutics (ONCT – Research Report), Adagene (ADAG – Research Report) and Omega Therapeutics (OMGA – Research Report).

Oncternal Therapeutics (ONCT)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Oncternal Therapeutics. The company’s shares closed last Thursday at $0.30, close to its 52-week low of $0.26.

According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -5.8% and a 32.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Reviva Pharmaceuticals Holdings, and MoonLake Immunotherapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Oncternal Therapeutics with a $2.50 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Adagene (ADAG)

H.C. Wainwright analyst Arthur He CFA maintained a Buy rating on Adagene today and set a price target of $5.00. The company’s shares closed last Thursday at $1.36.

According to TipRanks.com, CFA ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -23.3% and a 24.2% success rate. CFA covers the Healthcare sector, focusing on stocks such as Calliditas Therapeutics, Poseida Therapeutics, and LAVA Therapeutics.

Adagene has an analyst consensus of Moderate Buy, with a price target consensus of $5.00.

Omega Therapeutics (OMGA)

In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Omega Therapeutics, with a price target of $11.00. The company’s shares closed last Thursday at $3.67, close to its 52-week low of $3.11.

According to TipRanks.com, Burns is ranked 0 out of 5 stars with an average return of -32.6% and a 19.0% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Springworks Therapeutics, and Atara Biotherapeutics.

Currently, the analyst consensus on Omega Therapeutics is a Moderate Buy with an average price target of $10.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ONCT:

• Oncternal Therapeutics reports Q2 EPS ,(15c) consensus (16c)
• Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results
• Oncternal Therapeutics (ONCT) Q2 Earnings Cheat Sheet
• Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results